All studies
CompletedPhase IInterventional

A study in healthy volunteers to investigate the safety and tolerability of a new test medicine (DES-9384)

Rheumatoid arthritis is a long-term condition that causes painful, swollen, and stiff joints. Researchers are developing a new medicine called DES-9384 to help treat this disease and other painful inflammatory conditions. Before testing it on patients, scientists must first see how it behaves in healthy people. This early study (Phase I) is looking for healthy men and women aged 18 to 55. Volunteers will take either the study drug or an inactive dummy pill (placebo). The main goals are to check that the drug is safe, see how well the body tolerates it, and measure how it moves through the bloodstream. Volunteers will stay at a specialist clinic for a short period, give blood and urine samples, and attend follow-up visits. Participants do not receive direct medical benefit, but their involvement helps scientists develop potential new treatments for the future.

At a glance

Status
Completed
Phase
Phase I
Sponsor
D. E. Shaw Research
Enrolment target
104
Start
13 Jul 2023
Estimated completion
29 Feb 2024

What is this study about?

Rheumatoid arthritis is an autoimmune condition where the body's defence system mistakenly attacks the lining of the joints. Over time, this leads to painful swelling, stiffness, and joint damage, most commonly in the hands, wrists, and feet. Current medicines can help, but they do not work for everyone, which is why scientists continue to search for newer and better treatments.

This clinical trial is evaluating an experimental medicine called DES-9384. This is an early 'first-in-human' Phase I trial. Before any new drug can be given to patients living with rheumatoid arthritis, doctors must carefully test it in a small group of healthy volunteers to check its safety profile.

By taking part, healthy volunteers help researchers understand how the human body absorbs, breaks down, and clears the medicine. Researchers will also test whether taking the medicine with food makes a difference to how it works. Although this study will not cure any disease today, it provides crucial information needed to decide whether the drug can safely move forward into larger patient trials.

Key takeaways

  • Tests an early-stage medicine (DES-9384) being developed for rheumatoid arthritis and pain.
  • Open to healthy adults aged 18 to 55 who meet specific weight and health checks.
  • Participants will receive either the study medicine or a dummy pill (placebo).
  • Requires a short stay of at least 48 hours at a clinic in the UK, plus follow-up visits.
  • Healthy volunteers do not get direct health benefits, but help advance future medical treatments.

Who may be eligible?

This study is looking for healthy men and women aged between 18 and 55 years. To take part, volunteers must have a body mass index (BMI) between 18.0 and 32.0 and weigh under 110 kg. Women taking part must not be pregnant or breastfeeding, and must be unable to have children (for example, post-menopausal or surgically sterile). Men and women must also agree to follow the trial's contraception guidelines.

You cannot take part if you have a history of serious medical conditions, such as heart, kidney, liver, breathing, stomach, or mental health problems. People who have had gallstones, gallbladder removal, or severe drug allergies are also excluded. Because testing requires regular blood checks, volunteers need veins that allow for easy blood sampling.

Certain parts of the study involve gentle skin tests on the forearm. Because of this, volunteers with severe skin problems, significant forearm tattoos, or past forearm surgery might not be eligible for specific groups.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 18 and 55 years old?
  2. Do you consider yourself to be in good general health?
  3. Is your weight under 110 kg (with a BMI between 18 and 32)?
  4. Are you free from serious heart, kidney, liver, or stomach problems?
  5. If female, are you not pregnant, not breastfeeding, and unable to have children?
  6. Are you willing to stay at a specialist clinic for at least two nights?
Answer every question to see your result.

What does participation involve?

Taking part involves several stages across 6 to 7 weeks. First, you attend a screening visit to check your health. If suitable, you will join either Part 1 (testing single doses) or Part 2 (testing daily doses for 7 days). You will take either the study drug or a placebo (a dummy pill containing no active drug) by mouth. You will stay at the clinic for at least 48 hours after dosing so doctors can monitor you closely. Staff will regularly check your blood pressure, heart rhythm, and take blood and urine samples. After leaving the clinic, you will return 3 to 5 days later for a final check-up.

Potential risks and benefits

Because you are a healthy volunteer, you will not receive any direct medical benefit from taking DES-9384. However, your time helps medical science develop new treatments for people with joint disease. As with any new medicine, there is a risk of side effects, which could include mild stomach upset, headaches, or unforeseen reactions. You will be closely watched by medical staff throughout your stay to ensure your safety. Taking part is completely voluntary, and you can leave the trial at any point without giving a reason.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Quotient Sciences Limited
    City only
    Nottingham, England

Common questions

What is a Phase I clinical trial?

A Phase I trial is the earliest stage of testing a new medicine in humans. Its main purpose is to test safety, find out about side effects, and see how the body processes the drug.

What is a placebo?

A placebo looks just like the real medicine but contains no active ingredients. It helps researchers compare the true effects of the study drug against no treatment at all.

Will I have to stay overnight at the clinic?

Yes. Volunteers will stay at the research unit for at least two nights (48 hours) after dosing so the team can monitor safety and collect regular samples.

Can I leave the study if I change my mind?

Yes, taking part is entirely your choice. You are free to withdraw from the study at any time, and you do not have to provide a reason.

Do I need to have rheumatoid arthritis to take part?

No. This trial is specifically looking for healthy volunteers who do not have rheumatoid arthritis or other ongoing long-term conditions.

How to find out more

Fabrizio Giordanetto

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.